News stories about Biogen (NASDAQ:BIIB) have trended somewhat positive this week, Accern Sentiment reports. The research firm identifies positive and negative media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Biogen earned a daily sentiment score of 0.14 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 45.8605281705646 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
These are some of the media headlines that may have impacted Accern Sentiment Analysis’s scoring:
- Biogen Builds on Its 40-Year Legacy in Neuroscience with Presentation of Research from Its Portfolio of Medicines and … (businesswire.com)
- Biogen Builds on Its 40-Year Legacy in Neuroscience with Presentation of Research from Its Portfolio of Medicines and Investigational Programs for Neurodegenerative Diseases (finance.yahoo.com)
- Biogen (BIIB) Scheduled to Post Earnings on Tuesday (americanbankingnews.com)
- How Did Biogen Miss AveXis? (finance.yahoo.com)
- Factors of Influence in 2018, Key Indicators and Opportunity within McDonald’s, Biogen, Freeport-McMoRan … (globenewswire.com)
Several research firms have recently issued reports on BIIB. Deutsche Bank restated a “buy” rating and set a $373.00 price objective on shares of Biogen in a report on Friday, January 26th. Oppenheimer boosted their price objective on shares of Biogen from $380.00 to $400.00 and gave the stock a “buy” rating in a report on Friday, January 26th. Jefferies Group restated a “hold” rating on shares of Biogen in a report on Friday, January 26th. BMO Capital Markets reissued a “buy” rating on shares of Biogen in a research note on Thursday, January 25th. Finally, Cowen reissued a “buy” rating and issued a $408.00 target price on shares of Biogen in a research note on Friday, January 26th. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating and twenty-one have given a buy rating to the company. Biogen has an average rating of “Buy” and a consensus price target of $366.49.
Biogen (NASDAQ:BIIB) last issued its quarterly earnings data on Thursday, January 25th. The biotechnology company reported $5.26 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $5.44 by ($0.18). Biogen had a return on equity of 38.32% and a net margin of 20.69%. The company had revenue of $3.31 billion for the quarter, compared to the consensus estimate of $3.08 billion. During the same period in the prior year, the company earned $5.04 EPS. The firm’s revenue was up 15.1% on a year-over-year basis. sell-side analysts forecast that Biogen will post 24.85 earnings per share for the current year.
In other news, EVP Alfred Sandrock sold 259 shares of the stock in a transaction on Tuesday, February 27th. The shares were sold at an average price of $290.83, for a total transaction of $75,324.97. Following the completion of the sale, the executive vice president now owns 6,553 shares of the company’s stock, valued at $1,905,808.99. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold 2,296 shares of company stock valued at $678,993 in the last three months. 0.25% of the stock is owned by insiders.
COPYRIGHT VIOLATION NOTICE: “Somewhat Favorable Press Coverage Somewhat Unlikely to Affect Biogen (BIIB) Stock Price” was first reported by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The legal version of this story can be read at https://stocknewstimes.com/2018/04/17/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-biogen-biib-share-price.html.
Biogen Inc discovers, develops, manufactures, and delivers therapies for the treatment of neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis (MS); FUMADERM for the treatment of plaque psoriasis; and SPINRAZA to treat spinal muscular atrophy.
Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.